KRTX News and Press, Karuna Therapeutics Inc. From 11/01/23

2023-11-01 12:44:18 ET More on Karuna Therapeutics Karuna Therapeutics: KarXT Could Become A New Standard Of Care In Schizophrenia Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) For further details see: Karuna Therapeutics Q3 2023 Earni...

Analyses of pooled efficacy data from the EMERGENT program demonstrate significant improvements in schizophrenia symptoms Analyses extend prior findings that KarXT is generally well tolerated with a low risk of common adverse events associated with current antipsychotics, including somnol...

Karuna Therapeutics, Inc. (NASDAQ: KRTX), a biopharmaceutical company driven to discover, develop, and deliver transformative medicines for people living with psychiatric and neurological conditions, today announced that it will host a live conference call and webcast on Thursday, November 2, 202...

2023-10-16 14:41:21 ET Summary Karuna Therapeutics, Inc. stock had >8x gain after my Buy rating before successful Phase 3 trial data for KarXT in treating schizophrenia. The stock has pulled back and is at a good buy level ahead of the upcoming NDA decision (end of this year) a...

New efficacy, safety and tolerability analyses from the EMERGENT-3 trial support KarXT's potential as a new treatment option for schizophrenia Exploratory analysis will examine KarXT's impact on cognition in patients with schizophrenia in the EMERGENT-2 and EMERGENT-3 trials Compa...

2023-09-28 10:11:57 ET More on Karuna Therapeutics Karuna: NDA Filing Q3 Of 2023 And Expanded Potential With KarXT Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) Wells Fargo starts Karuna at overweight, cites schizophrenia drug candidate ...

KarXT, a dual M1/M4 muscarinic agonist, represents the first new mechanism of action to treat schizophrenia in several decades, if approved Submission is supported by data from three positive registrational trials demonstrating consistent and robust reductions of schizophrenia symptoms ...

2023-08-24 14:54:15 ET Summary Submission of New Drug Application of KarXT for the treatment of schizophrenia is expected in Q3, 2023. If FDA approval of KarXT is given for the treatment of patients with schizophrenia then commercial launch of the drug is expected in the second ha...

2023-08-22 17:22:02 ET More on Karuna Therapeutics Karuna's Robust Liquidity Paves Way For KarXT Milestones (Rating Upgrade) Karuna Therapeutics, Inc. ( KRTX ) Q2 2023 Earnings Call Transcript Karuna Therapeutics: Great Company, But Not A Great Buy Right Now ...

2023-08-16 17:08:23 ET Summary Karuna Therapeutics develops innovative treatments for psychiatric and neurological disorders, with their investigational drug KarXT targeting schizophrenia and Alzheimer's-related psychosis. Karuna Therapeutics faced a net loss of $103.2M in Q2 2023...